

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10693059	
	<b>Filing Date</b>		1993-10-23	
	<b>First Named Inventor</b>	Chownra		
	<b>Art Unit</b>	1645		
	<b>Examiner Name</b>	TBD		
<b>Attorney Docket Number</b>		03-465-A (400/136 CIP1)		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030143732		2003-07-31	Fosnaguh et al.	
	2	20050020521		2005-01-27	Rana et al.	
	3	20030064945		2003-04-03	Akhtar et al.	
	4	20030190635		2003-10-09	McSwiggen et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10693059
Filing Date	1993-10-23
First Named Inventor	Chowrira
Art Unit	1645
Examiner Name	TBD
Attorney Docket Number	03-465-A (400/136 CIP1)

1							<input type="checkbox"/>
---	--	--	--	--	--	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

## NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," Nature Biotechnology, 18:43-47 (2000)	<input type="checkbox"/>
	2	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," Eur. J. Biochem., 142(29):291-298 (1984)	<input type="checkbox"/>
	3	Caplen, Natasha J., "RNAi as a gene therapy approach," Expert Opin. Biol. Ther., 3(4):575-586 (2003)	<input type="checkbox"/>
	4	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," Nature, 2:110-119 (2001)	<input type="checkbox"/>
	5	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 18:307-319 (2000)	<input type="checkbox"/>
	6	Kumar et al., "Characterisation and expression of a PPI serine/threonine protein phosphatase (P(PP)) from the malaria parasite, Plasmodium falciparum: demonstration of its essential role using RNA interference," Malaria Journal, 1:5 (2002)	<input type="checkbox"/>
	7	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," Biochimica et Biophysica Acta, 1576, 101-109 (2002)	<input type="checkbox"/>
	8	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," J. Med. Chem., 36, 280-287 (1993)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10693059
Filing Date	1993-10-23
First Named Inventor	Chowrira
Art Unit	1645
Examiner Name	TBD
Attorney Docket Number	03-465-A (400/136 CIP1)

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.